Advaxis (ADXS) Names New COO

October 3, 2016 8:02 AM EDT
Get Alerts ADXS Hot Sheet
Trade ADXS Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Advaxis, Inc. (Nasdaq: ADXS) announced that Christopher Duke has joined the Company as Senior Vice President and Chief Operating Officer effective today. Duke, a biotech veteran with more than 20 years of life sciences experience, will lead operations at Advaxis with a focus on overseeing the company’s clinical development programs as well as managing early commercial planning activities.

With the addition of Duke, Executive Vice President Greg Mayes will step into the role of Chief Business Officer where he will continue to expand the company’s focus on identifying and executing on licensing, development, and collaboration opportunities for Advaxis’ Lm Technology™. Mayes will also oversee corporate strategy and lead the re-initiation of a company focus on leveraging the Advaxis technology for infectious disease programs.

Most recently, Duke served as Vice President, Global Commercial Operations at Amicus Therapeutics, Inc. where he played a lead role in the build out of the international business to support the successful launch of Galafold™ (migalastat), which was granted full approval by the European Commission earlier this year to treat patients with Fabry disease. As one of the first employees at Amicus, Duke held numerous leadership roles in program/alliance management, medical affairs and commercial planning over 10 years for multiple products across all stages of development.

In addition, Duke previously served as Executive Director, International Commercial Operations for NPS Pharma where he led several strategic business planning initiatives and helped to establish NPS International to support the ex-US commercialization of Revestive® (teduglutide) and Natpar® (rhPTH[1-84]).

“With experience in driving clinical development programs forward to product launch and managing interactions with the health care community, Chris has demonstrated his capabilities as a milestone-driven leader and will be a strong addition to the Advaxis team,” said Advaxis President and CEO Daniel J. O’Connor.

Duke received his MBA from the Wharton School, University of Pennsylvania, his MPH from the University of Medicine and Dentistry of New Jersey and a Bachelor of Science in chemical engineering from Rutgers University.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Management Changes, Management Comments

Related Entities

Twitter

Add Your Comment